CytoDyn Inc. (OTCMKTS:CYDY) Short Interest Update

CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) was the target of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 22,639,300 shares, a growth of 6.4% from the January 15th total of 21,272,500 shares. Based on an average trading volume of 11,699,700 shares, the short-interest ratio is presently 1.9 days.

CytoDyn Stock Up 5.1 %

CYDY traded up $0.01 during midday trading on Thursday, hitting $0.25. 1,842,706 shares of the company traded hands, compared to its average volume of 3,584,406. The firm has a market capitalization of $306.48 million, a PE ratio of -24.90 and a beta of 0.01. The company's 50-day moving average is $0.17 and its 200 day moving average is $0.15. CytoDyn has a 52 week low of $0.10 and a 52 week high of $0.32.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.